Study details
Enrolling now
Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells
Medical University of South Carolina
NCT IDNCT04061746ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
60
Study length
about 7.1 years
Ages
18–40
Locations
1 site in SC
About this study
This trial is testing the safety and effectiveness of a treatment using mesenchymal stem cells (MSCs) to help people with type 1 diabetes. The treatment involves infusing MSCs into participants, comparing it to a placebo infusion.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Mesenchymal Stem Cells (MSCs)
- 2.Receive Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)
PhasePhase 1
DrugMesenchymal Stem Cells (MSCs)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
Immunological Agents
Body systems
Endocrinology